Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 555 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: no Condition Clear all
Completed Phase 2 Interventional

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

NCT00002357
View directory record Official record
Conditions
HIV Infections
Interventions
HBY 097, Zidovudine
Drug
Lead sponsor
Hoechst Marion Roussel
Industry
Eligibility
13 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 5:02 AM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment

NCT01632436
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Pixantrone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 25, 2026, 5:02 AM EDT
Recruiting Not applicable Interventional

Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves

NCT02310399
View directory record Official record
Conditions
Hearing Loss, Bilateral (Causes Other Than Tumors)
Interventions
Nucleus ABI541 Auditory Brainstem Implant
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

NCT00687934
View directory record Official record
Conditions
Solid Tumors
Interventions
STA-9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
25 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Santa Monica, California • Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Clinical Trial Comparing Standard Wound Closure Techniques Versus TissuGlu® Surgical Adhesive

NCT01791504
View directory record Official record
Conditions
Disorder of Skin and/or Subcutaneous Tissue of Trunk
Interventions
TissuGlu Surgical Adhesive
Device
Lead sponsor
Cohera Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

NCT02277704
View directory record Official record
Conditions
PTSD
Interventions
TNX-102 SL, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 25, 2026, 5:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The DISCOVER INOCA Prospective Multi-center Registry

NCT05288361
View directory record Official record
Conditions
Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Interventions
Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

NCT00705926
View directory record Official record
Conditions
HIV Infections
Interventions
Highly Active Antiretroviral Therapy (HAART), No treatment
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Not applicable Interventional

No Opioids PrescrIptions On Discharge After Surgery

NCT04469868
View directory record Official record
Conditions
Opioid Use, Prescription Drug Abuse and Dependency, Surgery, Postoperative Pain
Interventions
No opioids at discharge
Behavioral
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 25, 2026, 5:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy Siblings

NCT00897078
View directory record Official record
Conditions
Leukemia
Interventions
laboratory biomarker analysis, medical chart review, metabolic assessment, questionnaire administration, assessment of therapy complications
Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
8 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy

NCT01639443
View directory record Official record
Conditions
Colon Cancer
Interventions
Predictive no-show overbooking
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 25, 2026, 5:02 AM EDT
Completed No phase listed Observational

Concussion in Motor Vehicle Accidents: The Concussion Identification Index

NCT02858544
View directory record Official record
Conditions
Motor Vehicle Accidents, TBI (Traumatic Brain Injury), Brain Contusion, Brain Injuries, Cortical Contusion, Concussion Mild, Cerebral Concussion, Brain Concussion, Accidents, Traffic, Traffic Accidents, Traumatic Brain Injury With Brief Loss of Consciousness, Traumatic Brain Injury With no Loss of Consciousness, Traumatic Brain Injury With Loss of Consciousness
Interventions
The Concussion Identification Index, ImPACT
Other
Lead sponsor
Clionsky Neuro Systems Inc.
Industry
Eligibility
10 Years to 60 Years
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Gyngerlean Supplementation on Energy Expenditure

NCT06805201
View directory record Official record
Conditions
No Disease or Condition is Being Studied, Metabolism
Interventions
Gyngerlean
Dietary Supplement
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

NCT03410030
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreas Metastases
Interventions
High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2, High Dose Ascorbic Acid 56.25 g/m^2, High Dose Ascorbic Acid 75 g/m^2
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

NCT00352430
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Nitric Oxide/INP Pulse Delivery, Nitric Oxide/INO Pulse Delivery
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

NCT01434498
View directory record Official record
Conditions
Chronic Genotype 1a or 1b HCV Infection
Interventions
GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule
Drug · Device
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Beverly Hills, California • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Comparison of Captivator Tissue Cassettes vs. no Cassettes for Endoscopic Mucosal Resection in Esophageal Carcinoma

NCT02911363
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
Captivator cassette, Standard of Care
Device · Other
Lead sponsor
AdventHealth
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 25, 2026, 5:02 AM EDT
Active, not recruiting Phase 3 Interventional

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

NCT04019327
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Talazoparib, Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

NCT00479674
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane, Bevacizumab, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Charlotte, North Carolina • Concord, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

NCT01685268
View directory record Official record
Conditions
Prostate Cancer
Interventions
AT13387, abiraterone acetate, Prednisone
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Los Angeles, California • Stanford, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

NCT02539108
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 25, 2026, 5:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects

NCT00840723
View directory record Official record
Conditions
Respiratory Diseases
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 25, 2026, 5:02 AM EDT